Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
The latest update is out from Trevi Therapeutics ( (TRVI) ).
Trevi Therapeutics, a biopharmaceutical company focused on chronic cough treatments, has announced key executive changes with James Cassella joining as Chief Development Officer and David Clark stepping down as Chief Medical Officer but continuing as a consultant. The company’s investigational therapy, Haduvio, aims to address unmet medical needs in chronic cough conditions and is advancing towards pivotal development and potential regulatory submission. Cassella’s extensive experience in CNS drug development is expected to significantly contribute to Haduvio’s progress.
For a thorough assessment of TRVI stock, go to TipRanks’ Stock Analysis page.